These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12404698)

  • 1. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
    Takahashi H; Sugita T; Higuchi H; Shimizu T
    Hum Psychopharmacol; 2002 Mar; 17(2):95-8. PubMed ID: 12404698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center.
    Silver H; Bilker WB
    J Clin Psychopharmacol; 2013 Oct; 33(5):710-1. PubMed ID: 23899641
    [No Abstract]   [Full Text] [Related]  

  • 3. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.
    Hirose S; Ashby CR
    J Clin Psychiatry; 2002 Aug; 63(8):733-6. PubMed ID: 12197455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.
    Lu ML; Chen TT; Kuo PH; Hsu CC; Chen CH
    Schizophr Res; 2018 Mar; 193():126-133. PubMed ID: 28688742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Effect of Fluvoxamine in Patients With Schizophrenia Under Risperidone Treatment: A Clinical Trial.
    Haji Seyed Javadi A; Shafikhani AA; Zamir SM; Khanshir ZF
    J Clin Psychopharmacol; 2018 Apr; 38(2):119-124. PubMed ID: 29432331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.
    Miyamoto S; Miyake N; Ogino S; Endo T; Yamaguchi N
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):702-3. PubMed ID: 18081639
    [No Abstract]   [Full Text] [Related]  

  • 8. Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.
    Chaichan W
    Psychiatry Clin Neurosci; 2004 Aug; 58(4):364-8. PubMed ID: 15298648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.
    Niitsu T; Fujisaki M; Shiina A; Yoshida T; Hasegawa T; Kanahara N; Hashimoto T; Shiraishi T; Fukami G; Nakazato M; Shirayama Y; Hashimoto K; Iyo M
    J Clin Psychopharmacol; 2012 Oct; 32(5):593-601. PubMed ID: 22926591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
    Lu ML; Lane HY; Chen KP; Jann MW; Su MH; Chang WH
    J Clin Psychiatry; 2000 Aug; 61(8):594-9. PubMed ID: 10982203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
    Dwivedi S; Pavuluri M; Heidenreich J; Wright T
    J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
    [No Abstract]   [Full Text] [Related]  

  • 18. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study.
    Silver H; Shmugliakov N
    J Clin Psychopharmacol; 1998 Jun; 18(3):208-11. PubMed ID: 9617979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
    Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.